In a recent shake-up, China rolled out the “4+7” bulk-buying policy in an effort to drive down prices of generic drugs and force local players to become more globally competitive by investing in more R&D. What does China's new healthcare policy mean for established multinational and Chinese pharmaceutical companies? CKGSB Professor of Finance Li Haitao explains.
Date: 2019.10.28 Time: 19:30-21:30 Location: Lotte Hotel Seoul, 30 Eulji-ro, Jung-gu, 04533 Seoul
Date: 2019.10.26 Time: 14:00-15:30 Location: Saint Marc Café, Sumitomo Realty & Development Shinjuku Grand Tower store, Tokyo (サンマルクカフェ住友不動産新宿グランドタワー店)
Founding Dean Xiang Bing will join 30+ high-ranking government officials, corporate chiefs and entrepreneurs like China's Former Minister of Commerce, President of the US-China Business Council and Former United States Ambassador to Singapore to debate how the global economic, social and technological landscapes will evolve during this time of immense competition and conflict between these two rival superpowers, and establish a framework for rebuilding positive, albeit competitive, dialogue between them. Click for 30% off.
A book launch event that will feature several of CKGSB’s seasoned professors and leading companies addressed in English Case Book China In Transition. Join us for an eye-opening discussion on how Chinese companies are transforming and the corresponding shifting role and strategy of multinationals in China.